A 17‐Beta‐Hydroxysteroid Dehydrogenase 13 Variant Protects From Hepatocellular Carcinoma Development in Alcoholic Liver Disease

Jie Yang, Eric Trépo, Pierre Nahon, Qian Cao, Christophe Moreno, Eric Letouzé, Sandrine Imbeaud, Quentin Bayard, Thierry Gustot, Jacques Deviere, Paulette Bioulac‐Sage, Julien Calderaro, Nathalie Ganne‐Carrié, Alexis Laurent, Jean Frédéric Blanc, Erwan Guyot, Angela Sutton, Marianne Ziol, Jessica Zucman‐Rossi, Jean‐Charles Nault – 25 March 2019 – Recently, a loss of function variant (rs72613567) in 17‐beta‐hydroxysteroid dehydrogenase 13 (HSD17B13) has been identified as protective of nonalcoholic (NAFLD) and alcoholic liver disease (ALD).

Telemedicine: An Evolving Field in Hepatology

Cindy Piao, Norah A. Terrault, Souvik Sarkar – 25 March 2019 – Healthcare delivery has been dramatically changing in recent times with advances in technology. One area of expansion has been the use of telemedicine due to progression in communication technologies. Telemedicine offers the opportunity to overcome barriers of access, improve patient satisfaction, improve healthcare outcomes and streamline communication between patients and providers.

Impact of Chronic Kidney Disease on Outcomes in Cirrhosis

Florence Wong, K. Rajender Reddy, Jacqueline G. O’Leary, Puneeta Tandon, Scott W. Biggins, Guadalupe Garcia‐Tsao, Benedict J. Maliakkal, Jennifer C. Lai, Michael B. Fallon, Hugo E. Vargas, Ram Subramanian, Paul J. Thuluvath, Patrick S. Kamath, Leroy Thacker, Jasmohan S. Bajaj – 25 March 2019 – We hypothesize that the prevalence of chronic kidney disease (CKD) among patients with cirrhosis has increased due to the increased prevalence of CKD‐associated comorbidities, such as diabetes.

Patients With Acute on Chronic Liver Failure Grade 3 Have Greater 14‐Day Waitlist Mortality Than Status‐1a Patients

Vinay Sundaram, Parth Shah, Robert J. Wong, Constantine J. Karvellas, Brett E. Fortune, Nadim Mahmud, Alexander Kuo, Rajiv Jalan – 25 March 2019 – Patients listed for liver transplantation (LT) as status 1a currently receive the highest priority on the waiting list. The presence of acute on chronic liver failure (ACLF) with three or more organs failing (ACLF‐3) portends low survival without transplantation, which may not be reflected by the Model for End‐Stage Liver Disease‐Sodium (MELD‐Na) score.

Sirtuin‐1/Mitochondrial Ribosomal Protein S5 Axis Enhances the Metabolic Flexibility of Liver Cancer Stem Cells

Zhihao Wei, Jiankun Jia, Gang Heng, Huailong Xu, Juanjuan Shan, Guiqin Wang, Chungang Liu, Jianyu Xia, Haijun Zhou, Min Wu, Zhi Yang, Meiling Wang, Zhouxing Xiong, Hong Huang, Limei Liu, Cheng Qian – 22 March 2019 – Metabolic reprogramming endows cancer cells with the ability to adjust metabolic pathways to support heterogeneously biological processes. However, it is not known how the reprogrammed activities are implemented during differentiation of cancer stem cells (CSCs).

Acute Severe Autoimmune Hepatitis: Corticosteroids or Liver Transplantation?

Mussarat N. Rahim, Rodrigo Liberal, Rosa Miquel, Nigel D. Heaton, Michael A. Heneghan – 22 March 2019 – Acute severe presentations of autoimmune hepatitis (AIH) represent a challenge for the transplant community. As a disease, it is poorly characterized, and there is a weak evidence base to guide diagnosis and treatment. Early identification of acute severe AIH is key because it determines the initiation of corticosteroids, which can be lifesaving. However, their use in this setting remains controversial.

Subscribe to